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Introduction
Gene therapy as a supplement or alternative to often unsatisfactory conventional methods for the treatment of cancer has been emerging during the past years. The HSVtk/GCV system is among the oldest concepts for cancer gene therapy. 1 It is broadly applicable, efficient and has been extensively studied during the last decade (for a recent review see Ref. 2) . The therapeutic principle of the tk gene approach consists of the transfer of the HSVtk gene into cancer cells with subsequent expression of the tk gene and synthesis of an enzyme that specifically leads to toxification of an otherwise nontoxic prodrug (for instance ganciclovir, GCV) in cells performing DNA synthesis. Although the efficacy of this approach is enhanced by the bystander effect, which leads to 100% cell killing even if only 10% of the target cells are transduced, 3 efficient transfer of the tk gene into tumor cells will require the use of effective gene transfer vehicles such as adenoviral vectors.
Treatment of malignancies with an adenoviral vector which expresses the tk gene under transcriptional control of the human cytomegalovirus immediate-early promoter and subsequent GCV treatment has given excellent results in animal models. 4, 5 However, we recently
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The first two authors contributed equally to this work Received 13 January 1998; accepted 24 April 1998 reported severe toxicity upon the treatment of colorectal liver metastases with this Ad.CMV-HSVtk/GCV system. 6 The liver especially seems to be affected by this treatment, and the so far accepted view that toxified GCV should only kill proliferating cells apparently does not hold true for resting hepatocytes in vitro and in vivo. 6 Similar results concerning toxicity to the liver and the brain have, meanwhile, also been reported by others. [7] [8] [9] Liver-related toxicity accompanying the treatment of colorectal metastases could be of increasing relevance because in the long run local treatment of this disease which allows at least some confinement of the vector to the target tissue will, due to the disseminated nature of the disease, be substituted by regional or systemic vector infusions, a method of application that has already been applied with some success for the treatment of colorectal liver metastases with an adenovirally transferred p53 gene. 10 One possible way to circumvent problems connected with tk gene expression in hepatocytes after adenoviral gene transfer is to use tissue-specific regulatory elements thereby restricting tk gene expression to the tumor cell. For specific expression in colon tumor cells, the promoter of the carcino-embryonal antigen (CEA) seems particularly suitable. CEA is expressed by many tumors of colorectal origin, and it serves as a parameter for colorectal carcinoma reoccurrence in the clinic (for review see Ref. 11) . Moreover, the 5′ noncoding region has been studied extensively, and it has been shown that a fragment of about 400 bp length is sufficient to drive tissue-specific expression in colon tumor cells at a level comparable to that attainable with the SV40 promoter. 12, 13 The CEA promoter has been used for the construction of both expression plasmids and retroviral vectors, and a correlation of sensitivity of cells to toxified prodrugs with endogenous CEA production has been shown [13] [14] [15] (own unpublished findings).
In the present study, we show that the CEA promoter is a promising tool for driving tk gene expression in the treatment of colorectal liver metastases. The problem of liver toxicity of the tk gene approach is addressed, and a comparison of efficacy and toxicity of the CEA and the widely used CMV promoter is performed.
Results
Specific expression of the HSVtk gene driven by the CEA promoter in vitro First, we were interested in determining whether the specificity of the CEA promoter for colon tumor cells reported in earlier studies 12, 13 could be retained in the context of an E1-deleted adenoviral vector. To this end, a recombinant adenovirus (Ad.CEA-tk) was constructed in which the HSV1 thymidine kinase gene is driven by a 398 bp CEA promoter extending from −296 to +102 with respect to the transcription start site as reported in Ref. 13 . An RNase protection assay specific for the tk gene transcript was used to determine the level and cell type specificity of tk gene expression. Three tumor cell lines derived from human colon carcinomas (LoVo and LS174T) or rat (CC531) and several cell lines of different origin (Huh7, HepG2, HeLa, SEC, 293) were infected with Ad.CEA-tk or Ad.CMV-tk in which the HSV1 tk gene is under transcriptional control of the human cytomegalovirus immediate-early promoter. Ad.RSVbg in which expression of the E. coli lacZ gene is driven by the RSV promoter was used as a negative control. Two days later, cells were harvested, RNA was isolated and tk gene expression was determined. As expected, the CMV promoter allowed for a strong expression of the transgene in all cell lines ( Figure 1a ) with a significantly lower expression in LS174T cells. The low tk gene expression in LS174T cells is probably due to the sensitivity of this cell line to adenovirus infection at a high multiplicity of infection (MOI). In contrast, expression from the CEA promoter differed between cell lines and was about 10% of that obtained with the CMV promoter in LoVo and LS174T cells. However, another colon carcinoma-derived cell line (CC531) showed lower activity of the CEA promoter (about 2% of CMV promoter activity), and substantial tk gene expression from the CEA promoter was also observed in Huh7, HeLa, HepG2 and 293, which are not of colorectal origin. No CEA promoter activity was detectable in slowly dividing SEC cells and after infection with Ad.RSVbg.
To exploit a system which is closer to the in vivo situation than rapidly dividing liver-derived cell lines, we infected primary hepatocytes isolated from rat and rabbit with the tk vectors at an MOI of 50 and determined transgene expression 2 days later (Figure 1b) . Again, infection with Ad.CMV-tk led to a strong signal specific for the tk transcript in the RNase protection assay. However, in contrast to the liver cell lines examined the signal in primary hepatocytes after infection with Ad.CEA-tk was almost undetectable. These results indicate that the CEA promoter displays only little specificity for colon tumor cells when compared with other carcinoma cell lines but is highly specific when compared with primary hepatocytes, where it seems to be almost inactive. Moreover, in our hands this promoter is rather weak exhibiting 2-10% of CMV promoter activity.
The CEA promoter is inactive in liver tissue but active in colon tumors Although the activity of the CEA promoter was rather low as compared with the strong CMV promoter, the nearly complete lack of CEA promoter-dependent expression in primary hepatocytes in vitro encouraged us to examine the activity and specificity of the CEA promoter in vivo. Earlier results showed that systemic application of Ad.CMV-tk and subsequent GCV treatment resulted in severe liver toxivity and subsequent death in mice. 6 To be able to compare the CMV and CEA promoters with respect to their activity and toxicity, a 20-fold higher dose of Ad.CEA-tk as compared with Ad.CMV-tk was used for all in vivo experiments. This compensated for the weak activity of the CEA promoter. On the other hand, reducing the dose of Ad.CMV-tk was expected to result in a decreased toxicity of the GCV treatment. Figure 2 shows the result of an initial experiment. Mice were infected via the tail vein with 7.5 × 10 8 p.f.u. of Ad.CMV-tk or 1.5 × 10 10 p.f.u. of Ad.CEA-tk. The same doses of Ad.RSVbg were previously shown to result in transgene expression in 10 or 100% of hepatocytes, respectively. 5, 16 Four days after adenovirus administration, animals were killed and DNA and RNA were isolated separately from the same liver pieces. Southern hybridization with a probe specific for adenovirus DNA resulted in signals which paralleled the adenovirus dose administered (Figure 2a) . Analysis of tk transcripts revealed significant expression of the tk gene in mouse liver when expression was driven by the CMV promoter, whereas -despite the high viral dose -no tk transcripts were detected in liver when expression was controlled by the CEA promoter ( Figure 2b ). We conclude from these results that the CEA promoter is silent in mouse liver.
To test if the higher virus dose could compensate for the weak activity of the CEA promoter in tumor cells we analyzed tk expression after adenoviral transduction of LS174T-derived subcutanously growing tumors in SCID mice. Tumors were infected with 7.5 × 10 8 p.f.u. of Ad.CMV-tk or 1.5 × 10 10 p.f.u. of Ad.CEA-tk, DNA and total RNA were isolated separately from the same tumors and virus DNA, as well as tk transcripts were analyzed. In contrast to the results obtained in liver tissue, transduced tumors displayed significant signals for tk-specific transcripts after transduction with both viruses, and CEA promoter-driven tk gene expression was about 30% of that obtained with the CMV promoter ( Figure 3b ). The still lower activity of Ad.CEA-tk, despite the application of the 20-fold adenoviral dose, may be due to the mode of interstitial application of virus which could prevent a linear relationship of applied adenoviral dose and adenovirus infection. Moreover, a saturation of CEA promoter activity due to the limited availability of a transcription factor or a saturation of adenoviral receptors cannot be ruled out. Efficient gene transfer of Ad.CEA-tk to the liver does not lead to any toxicity upon GCV treatment We next examined whether the lack of tk expression after 100% tk gene transfer into hepatocytes upon Ad.CEA-tk application would be paralleled by a lack of toxicity of GCV treatment. Moreover, we wanted to know if reduction of the dose of Ad.CMV-tk in comparison with earlier experiments 6 would reduce the toxicity of CMV promoter-driven tk gene expression in the liver with subsequent GCV treatment. To this end, we applied 7.5 × 10 8 p.f.u. of Ad.CMV-tk or 1.5 × 10 10 p.f.u. of Ad.CEA-tk, respectively, via the tail vein to mice. All animals injected with Ad.CEA-tk survived a 10-day GCV treatment schedule (2 × 75 mg/kg per day; Figure 4 ) without any signs of liver toxicity (data not shown). In contrast, all mice treated with a 20-fold lower dose of Ad.CMV-tk died within 4 days of GCV treatment and showed extensive signs of hydropic liver degeneration as described before (Ref. 6 and data not shown). We conclude that even a low dose of Ad.CMV-tk is sufficient to cause severe liver toxicity after GCV treatment, whereas a high dose of Ad.CEA-tk does not cause any signs of toxicity.
Ad.CEA-tk confers GCV sensitivity to colon tumor cells As a next step we investigated whether the activity of the CEA promoter in an adenoviral context would be sufficient to drive tk gene expression to levels required to kill target tumor cells. In preliminary experiments, three colon tumor cell lines were tested with Ad.RSVbg for their infectability with adenovirus (data not shown). According to these results, the cells were infected with MOIs of Ad.CEA-tk or Ad.CMV-tk leading to 60 or 20% gene transfer, respectively, and GCV at increasing doses was added to the medium 1 h after infection. The survival rate of cells was assessed 5 or 6 days later ( Figure 5 ). In the case of Ad.CEA-tk, almost 100% cell killing was achieved in all cell lines even when only 20% of cells were transduced, which indicates a strong bystander effect. However, complete killing of transduced cells required the presence of comparatively high concentrations of GCV. As expected from our expression studies, reduction of cell survival was obtained at lower GCV concentrations when cells were transduced with Ad.CMV-tk. The GCV concentration at which 50% cell survival is seen (IC 50 ) was up to 150-fold lower for Ad.CMV-tk than for Ad.CEA-tk ( Table 1 ). The high ratio of IC 50 between the two viruses at the lower transduction rate (20%) in CC531 cells, which exhibit a strong bystander effect (own unpublished data), indicates a strong dependence of the bystander effect on promoter strength. These results also indicate that CEA promoterdriven tk gene expression is sufficient to confer GCV sensitivity to target cells, but comparatively high concentrations of GCV are required.
Ad.CEA-tk leads to growth retardation of subcutaneously growing tumors To evaluate the efficacy of CEA promoter-driven tk gene expression in vivo, we established LS174T-derived human colon carcinomas in SCID mice and injected 1.5 × 10 10 p.f.u. of recombinant adenoviruses (as indicated) directly into the growing tumors. After 10 days of GCV treatment, tumors were harvested and tumor volumes were determined ( Figure 6 ). In the main treatment group, that received Ad.CEA-tk and GCV, the mean tumor volume was about 16% of the control group that had received neither virus nor GCV treatment (P Ͻ 0.01). The best results were obtained with animals that had received Ad.CMV-tk (P Ͻ 0.01). In this group, three of five animals displayed nearly complete tumor regression and one animal showed significant tumor growth retardation. Due to one nonresponding animal, that carried a big tumor, the difference from the Ad.CEA-tk group was not significant, but reached significance (P Ͻ 0.05) when this animal was excluded from the group. Application of GCV alone had minor effects (NS) on tumor growth. Infection of tumors with adenovirus alone reduced tumor growth by nearly 50% (Ad.CMV-tk, P Ͻ 0.05; Ad.CEAtk, P Ͻ 0.05), indicating the high susceptibility of LS174T cells to adenoviral toxicity, which had already been observed in the in vitro assays (Figure 5b ). The combined treatment with Ad.RSVbg and GCV resulted in growth inhibition of more than 50% (P Ͻ 0.01) but the difference from the main treatment group (Ad.CEA-tk/GCV) remained significant (P Ͻ 0.05). These results indicate that the CEA promoter-driven tk gene expression leads to a pronounced retardation of tumor growth. However, efficacy is not as high as the one obtained with the CMV promoter.
Discussion
Based on our recent findings of severe liver toxicity of the HSVtk/GCV approach using adenoviral vectors for the treatment of colorectal liver metastases, 6 we evaluated, in this study, whether the replacement of the CMV promoter, which is active in the liver after adenovirus infection, by the colon tissue-specific CEA promoter would be a safe and efficient alternative. We show here: (1) that the CEA promoter is active in several tumor cell lines in vitro but nearly inactive in primary hepatocytes when placed in an adenoviral vector; (2) that the CEA promoter drives transgene expression in colon tumor tissue derived from tumor cell lines but not in the liver; (3) that the CEA promoter is safe with respect to liver toxicity of the tk gene/GCV approach even at subtoxic GCV doses; and (4) that a CEA promoter-driven tk gene has the capacity to kill tumor cells both in vitro and in vivo after GCV treatment. Maintenance as well as loss of tissue specificity of promoters after incorporation into the adenoviral genome has been reported previously. [17] [18] [19] [20] [21] [22] The incorporation of the CEA promoter/tk cassette into the adenoviral E1 region did not cause a significant change in the in vitro characteristics of this promoter. We found a moderate activity of a 400 bp CEA promoter in LoVo cells and an about five-fold weaker activity in other tumor cell lines including liver-derived cell lines Huh7 and HepG2. These findings are in agreement with the earlier results of Richards and co-workers 12 who reported an about four-fold lower activity of this promoter in Huh7 compared with LoVo in transient transfection assays. Thus, incorporation of the CEA promoter into the enhancer containing E1 region of the adenoviral vector did not neutralize cell type specificity of the CEA promoter. However, since Huh7 cells were reported by Richards et al 12 to produce CEA at an undetectable level it seems that the activity of the CEA promoter does not strictly parallel endogenous CEA production in liver tumor cell lines, which could be due to factors present in rapidly dividing cells. This idea is supported by the fact that no expression from the CEA promoter was observed in nondividing primary hepatocytes and in mouse liver. The lack of CEA promoter activity in nondividing hepatocytes makes it a good candidate for driving tk gene expression in conjunction with adenoviral gene transfer for the treatment of colorectal liver metastases.
Figure 5 GCV sensitivity of tumor cell lines transduced with Ad.CEA-tk or Ad-CMV-tk at three different MOIs. Cells were infected with Ad.CEAtk or Ad.CMV-tk at MOIs of 20 and 60 in the case of CC531 and LS174T cells or at MOIs of 5 and 15 in the case of LoVo cells, leading to a transduction rate of 20% and 60%. GCV was applied at various concentrations and 5-6 days later the number of surviving cells (percentage of untreated control) was determined by trypan blue exclusion assay.
One major concern in using the CEA promoter for tk gene expression is the low activity of this promoter when compared with the strong CMV promoter. One possible approach in overcoming this problem was to increase the virus dose, thereby increasing the copy numbers of viral genomes and of the transgene present in tumor cells. The use of a 20-fold higher dose of Ad.CEA-tk compared with Ad.CMV-tk resulted in good tk gene expression level after treatment of LS174T-derived tumors in vivo. Although this high dose of Ad.CEA-tk was safe with regard to liver toxicity upon treatment with GCV it did not result in complete tumor regression in our SCID mouse model. However, currently we do not know if the increase in virus dose correlates with an increased virus uptake into the tumor. Although we observed a strict parallelity of applied virus dose and strength of the respective Southern blot signals in tumors, we cannot preclude that part of the signal resulted from virus which did not enter tumor cells but was still present in the interstitial space. Moreover, LS174T cells exerted only weak CEA promoter activity which was not compensated for by the high virus dose applied to the tumors. While the present study was in progress, Tanaka and co-workers 25 reported growth reduction of MKN45-derived tumors by using a virus similar to Ad.CEA-tk. They achieved an effect on tumor growth comparable with that observed in our study with lower viral doses, which is probably due to the higher expression of the CEA promoter in this gastric tumor cell line as compared with LS174T.
Transduction with a high dose of Ad.CMV-tk had an about 10-fold stronger effect after local application into LS174T-derived tumors than transduction with Ad.CEAtk and caused nearly complete tumor growth regression. The good efficacy of the CMV promoter-driven tk gene expression on tumor growth is in agreement with earlier reports. 4 However, since we are planning to treat micrometastases of CEA-positive colon tumors in the liver by regional treatment, which can lead to infection of the whole liver with tk gene expressing adenovirus, the good result with Ad5CMV-tk has to be seen in the context of the toxicity problems with this virus.
Our in vitro toxicity studies show that an optimal therapeutic outcome with Ad.CEA-tk will require a high level of transduction efficiency. With an average IC 50 of 50 m under conditions of a gene transfer rate of 20%, the required GCV concentration is, already under in vitro conditions, above the tolerable peak serum levels of GCV in humans, which should not exceed 20 m. 23 However, any increase in transfer efficacy will reduce the required GCV concentration as the IC 50 at 60% transduction is only 20 m. In contrast, in the case of Ad.CMV-tk, the IC 50 under in vitro conditions of gene transfer into 20% of cells was below 1 m, a concentration which should be readily achieved in the clinical situation. Moreover, the efficacy of the bystander effect which is extremely important under conditions of less than 100% gene transfer seems to depend particularly on a high expression level of the tk gene. These differences between Ad.CEA-tk and Ad.CMV-tk are reflected by our in vivo results, where under conditions of less than 100% gene transfer (data not shown), the attainable GCV concentrations are obviously sufficient to nearly completely suppress tumor growth in the case of Ad.CMV-tk, but only sufficient to kill heavily infected cells in the case of Ad.CEA-tk.
Therefore, we think that modifications of the CEA promoter to increase its strength while maintaining specificity would be beneficial to make it more suitable for clinical use. An increase of promoter activity has been achieved by promoter engineering. 12 Although the increase in promoter strength could not be fully converted into a linear increase in GCV sensitivity, this approach could potentially be applied to adenoviral vectors. Moreover, any increase in affinity between transgene product and drug 24 will compensate for promoter weakness without any loss of specificity.
In summary, the lack of any toxicity argues strongly in favor of the CEA promoter, especially if regional or even systemic treatment of colorectal liver metastases becomes the preferred mode of vector application. 10 Although the efficacy of Ad.CMV-tk, allowing a complete growth suppression of subcutaneous tumors, is impressive, safety concerns do not allow recommendation of this vector for clinical use in the liver at this time. We are currently trying to increase promoter strength of the Ad.CEA-tk construct by inclusion of additional promoter elements. Alternative strategies would be to circumvent the problem by providing the adenoviral vector with tissue-specific replication ability or to increase the affinity of suicide gene and target drug.
Materials and methods

Preparation of recombinant adenovirus
Ad.CMV-tk was generated as described previously. 6 Ad.RSVbg (Ad-␤gal 25 ) was generously provided by LO Stratford-Perricaudet (Institute Gustave Roussy, Villejuif, France) and contains the RSV promoter-driven E. coli lacZ gene. For generation of Ad.CEA-tk the 2.8 kb HindIII fragment from plasmid pCEAtk, in which the HSV1 thymidine kinase gene is expressed under the control of the CEA promoter (−296 to +102 with respect to the transcription start site), was inserted into the HindIII site of p⌬E1sp1B 26 and the resulting plasmid was cotransfected with pJM17 27 into 293 cells. Recombinant adenovirus was plaque purified, and large virus stocks were generated as described earlier. 19 Virus titers were determined by a modified end-point cytopathic effect (c.p.e) assay 28 on 293 cells.
Cell lines and isolation of primary hepatocytes
The LS174T and LoVo cells are human colon adenocarcinoma cell lines. CC-531 was obtained through the courtesy of R Rezka (MDC, Berlin, Germany) and is a methylazoxymethanol-induced, moderately differentiated and weakly immunogenic adenocarcinoma of the colon, tumorigenic in WAG/Rij rats. 29, 30 All three cell lines were cultured in RPMI (Gibco BRL Germany, Berlin, Germany) supplemented with 10% FCS, glutamine (2 mm), penicillin (100 IU/ml) and streptomycin (50 g/ml). HeLa (human epitheloid carcinoma of the cervix), Huh7 and HepG2 (human hepatoma), SEC (human sinus endothelial cells), and HEK 293 (human embryonal kidney, adenovirally transformed) were cultured in DMEM supplemented as described above.
For rat hepatocyte isolation, a modification of the method of Glatt et al 31 was applied. Briefly, livers were perfused in situ with a calcium-free buffer containing 5 mm EDTA at 37°C with a constant flow rate of 10 ml/min for 15 min, followed by a perfusion buffer containing 6 mg/ml collagenase (Boehringer Mannheim, Mannheim, Germany) and 3 mm calcium chloride for another 15 min. The liver was excised, placed in Grey's balanced salt solution (GBSS), and the liver capsule was disrupted to free the partially digested contents. For isolation of rabbit hepatocytes one liver lobe was isolated, a large supporting vessel was selected and perfusion was performed as described above. Cell suspensions were filtered through a 100-m mesh filter, and the filtrate was centrifuged at 50 g for 5 min. The pellet was resuspended twice in GBSS and recentrifuged to remove nonparenchyma cells. The final pellet was dispersed in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FCS, glutamine (2 mm) and penicillin (100 IU/ml)/streptomycin (50 g/ml). Hepatocytes were plated at a density of 1-3 × 10 6 per well on collagencoated 10-cm culture plates. After 4 h, when the cells had attached to the culture plates, DMEM was removed and replaced by MX-83 media supplemented with EGF (10 ng/ml), insulin (1 g/ml) and hydrocortisone (0.5 g/ml).
Determination of cellular susceptibility to adenoviral transduction and of GCV sensitivity Cells (7.5 × 10 4 per well) were plated on 24-well tissue culture plates. Twenty-four hours later, cells were infected with Ad.RSVbg at various MOIs. After 72 h, the infected cells were stained with X-gal and the percentage of blue staining cells was determined.
For determination of GCV sensitivity after adenoviral transfer of the tk gene, cells were infected with Ad.CEAtk or Ad.CMV-tk at MOIs of 20 and 60 in the case of CC531 and LS174T or at MOIs of 5 and 15 in the case of LoVo, leading to a transduction rate of 20 or 60%. Subsequently, GCV was applied at various concentrations and 5-6 days later the percentage of surviving cells (% of untreated control) was determined by trypan blue exclusion assay. The IC 50 was determined graphically and refers to virus-infected, non-GCV-treated cells.
Animal studies
All experiments were performed with SCID mice (C.B-17/Icr/BlnA-scid/scid, own breeding). Subcutaneous tumors were induced by injection of 2 × 10 6 LS174T into the left flank of the animals. Once tumors of about 50 mm 3 had grown, mice were anesthetized with 40 mg/kg Etomidat (Arzneimittelwerk Dresden, Dresden, Germany). After incision of the skin, the exposed tumors were injected with 1.5 × 10 10 p.f.u. (50 l) of the adenoviral vectors as indicated. The next day, GCV treatment was started and mice received 75 mg/kg GCV by intraperitoneal injection for 10 days. After this period, mice were killed and tumor volumes were calculated after measurement in two dimensions according to the formula v = a × b/2 with b р a. Statistical analysis was performed applying Student's t test.
For determination of adenoviral gene transfer and transgene expression in tumors, 1 × 10 6 LS174T cells were injected into the left flank of SCID mice. When tumors had reached a volume of about 100 mm 3 , anesthesia was performed and after incision of the skin 3 × 10 10 p.f.u. Ad.CEA-tk or 1.5 ⁄ 10 9 p.f.u. Ad.CMV-tk were injected into the growing tumors.
For determination of tk gene expression in mouse liver, SCID mice received injections of either 7.5 × 10 8 Ad.CMVtk or 1.5 × 10 10 Ad.CEA-tk into the tail vein. Three days later, animals were killed, livers were harvested and DNA and RNA were analyzed for the presence of adenoviral genomes or transgene expression, respectively. To evaluate in vivo toxicity of the systemic application of Ad.CEA-tk or Ad.CMV-tk, SCID mice received injections of the same viral doses as described above into the tail vein. Twenty-four hours later, GCV treatment (2 × 75 mg/kg per day) was started and was continued for 10 days. The livers of animals killed by the therapy or those which survived were evaluated histopathologically.
Southern blotting and RNase protection assay Total RNA was prepared from cells infected 48 h before with adenoviral vectors at an MOI of 50 (LoVo, CC531, HeLa, Huh7, LS174T, HepG2, SEC and primary hepatocytes ) or at an MOI of 5 (293). For preparation of RNA and DNA from liver or tumors, tissue was frozen in liquid nitrogen immediately after removal, homogenized on liquid nitrogen, and genomic DNA and total RNA were prepared separately from the same piece of tissue. Southern blotting for detection of adenovirus DNA was performed as described previously. 20 For preparation of a tk-specific RNA probe, the internal BalI fragment from the tk gene was cloned into the EcoRV site of pBluescript (Stratagene, Heidelberg, Germany) resulting in pBStk. Linearization of pBStk with HindIII and subsequent in vitro transcription with T3 polymerase gives rise to a 402 base probe protecting tk RNA at a length of 294 bases. Linearization of pBStk with XbaI and transcription with T7 polymerase results in a sense RNA which is protected by the same probe at a length of 373 bases and which was used as a standard for quantification of tk-specific RNA signals. RNase protection assay was performed with 2-10 g of total RNA using the RPA II TM kit (Ambion, Wiesbaden, Germany) according to the manufacturer's protocol. Hybridization was carried out overnight at 52°C.
